

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thastrup et al.

Serial No.: 08/819,612

Group Art Unit: 1806

Filed: March 17, 1997

Examiner: Ungar, S.

For: Novel Fluorescent Proteins

VERIFIED STATEMENT UNDER 37 CFR 1.821(f)

Hon. Commissioner of Patents and Trademarks
Washington, DC 20231


Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issue thereon.

Respectfully submitted,

Date: October 15, 1997


Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123